What is the Alzheimer's Disease Therapeutics Market?

The Alzheimer's Disease Therapeutics Market refers to the industry focused on developing and providing treatments for Alzheimer's disease, a neurodegenerative condition affecting memory and cognitive function.

How big is the Alzheimer’s Disease Therapeutics Market?

The global Alzheimer’s Disease Therapeutics Market size was estimated at USD 5.5 Billion in 2023 and is expected to reach USD 30.8 Billion in 2033.

What is the Alzheimer’s Disease Therapeutics Market growth?

The global Alzheimer’s Disease Therapeutics Market is expected to grow at a compound annual growth rate of 18.8%. From 2024 To 2033

Who are the key companies/players in the Alzheimer’s Disease Therapeutics Market?

Some of the key players in the Alzheimer’s Disease Therapeutics Markets are Eisai Co., Ltd., Novartis AG, AbbVie Inc. (Allergan Plc.), Adamas Pharmaceuticals, Inc., H. Lundbeck A/S, Biogen, AC Immune, F. Hoffmann La Roche Ltd., Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., TauRx Pharmaceuticals Ltd. Other Key Players.

What types of therapeutics are commonly used for Alzheimer's disease?

Common therapeutics for Alzheimer's disease include cholinesterase inhibitors and NMDA receptor antagonists, aimed at managing symptoms and slowing disease progression.

Are there any promising advancements in Alzheimer's therapeutics?

Emerging therapies, including monoclonal antibodies and disease-modifying drugs, show promise in addressing the underlying causes of Alzheimer's disease, offering hope for more effective treatments.

What role does research and development play in this market?

Research and development efforts are critical in advancing Alzheimer's therapeutics, as they lead to the discovery of new drugs and treatment approaches, driving market growth.

Global Alzheimer’s Disease Therapeutics Market By Drug Class (Cholinesterase inhibitors, NMDA Receptor Antagonist Combination Drug, and Pipeline Drugs), By Disease Stage (Preclinical Alzheimer's Disease, Mild Cognitive Impairment (MCI), Mild Dementia Due to AD, Moderate Dementia Due to AD, and Severe Dementia Due to AD), By Route of Administration, By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Jan 2024
Report ID: 105553
Number of Pages: 275
Format:

- Eisai Co., Ltd.
- Novartis AG Company Profile
- AbbVie Inc. (Allergan Plc.)
- Adamas Pharmaceuticals, Inc.
- Lundbeck A/S
- Biogen
- AC Immune
- Hoffmann La Roche Ltd.
- Daiichi Sankyo Company, Limited
- Johnson & Johnson Services, Inc.
- TauRx Pharmaceuticals Ltd.
- Other Key Players
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 105553
Published Date Jan 2024
Rating
- ★★★★★
  
  ★★★★★
- (63)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)